



(51) International Patent Classification:

C07D 265/30 (2006.01) **A61K 31/4965** (2006.01)
C07D 261/14 (2006.01) **A61K 31/495** (2006.01)
C07D 241/04 (2006.01) **A61K 31/44** (2006.01)
C07D 237/20 (2006.01) **A61K 31/42** (2006.01)
C07D 231/12 (2006.01) **A61K 31/4155** (2006.01)
C07C 233/00 (2006.01) **A61P 25/16** (2006.01)
C07C 223/00 (2006.01) **A61P 25/28** (2006.01)
A61K 31/5375 (2006.01) **A61P 25/00** (2006.01)

(21) International Application Number:

PCT/CN2010/001501

(22) International Filing Date:

27 September 2010 (27.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/246,550 29 September 2009 (29.09.2009) US
 PCT/CN2010/001334
 2 September 2010 (02.09.2010) CN

(71) **Applicant** (for all designated States except PG, US):
GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(71) **Applicant** (for PG only): **GLAXOSMITHKLINE (CHINA) R&D COMPANY LIMITED** [CN/CN]; No. 3 Building, 898 Halei Road, Zhang Jiang Hi Tech Park, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **NICHOLS, Paula Louise** [GB/GB]; c/o GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **EATHERTON, Andrew John** [GB/GB]; c/o GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **BAMBOROUGH, Paul** [GB/GB]; c/o GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brent-

ford Middlesex TW8 9GS (GB). **JANDU, Karamjit Singh** [GB/GB]; c/o GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **PHILPS, Oliver James** [GB/GB]; c/o GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **ANDREOTTI, Daniele** [IT/GB]; c/o GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(74) **Agent:** **KING & WOOD PRC LAWYERS**; 31/F, Office Tower A, Jianwai SOHO, 39 Dongsanhuan Zhonglu, Chaoyang District, Beijing 100022 (CN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) **Title:** NOVEL COMPOUNDS

(57) **Abstract:** The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.



WO 2011/038572 A1